Company intelligence / Profile preview

Repare Therapeutics

Cambridge, Massachusetts, United Statesreparerx.com ↗

Ownership: Public · RPTX
Employees: ~34
Development stage: Phase 1

Overview

The company has multiple clinical programs with promising results. Their lunresertib and camonsertib combination showed positive results in Phase 1 trials for endometrial and ovarian cancer patients, with overall response rates of 25.9% and 37.5% respectively. The company has reprioritized its pipeline to focus on RP-1664 and RP-3467, with data from the POLAR trial expected in Q3 2025.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

6 assets

camonsertib

5 more assets in the full pipeline.

Partnerships

Previously partnered with Roche (terminated in May 2024)DCx Biotherapeutics (out-licensing of discovery platforms announced May 1, 2025)

Beyond the preview

Go deeper on Repare Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Repare Therapeutics.